Holocene Advisors LP grew its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 432.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,944 shares of the company's stock after purchasing an additional 32,445 shares during the quarter. Holocene Advisors LP owned about 0.07% of LivaNova worth $2,099,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Primecap Management Co. CA increased its position in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company's stock worth $327,889,000 after buying an additional 44,049 shares during the period. Point72 Asset Management L.P. grew its holdings in LivaNova by 204.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock worth $70,479,000 after acquiring an additional 863,157 shares during the period. Victory Capital Management Inc. grew its holdings in LivaNova by 16.6% during the 3rd quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock worth $49,130,000 after acquiring an additional 133,401 shares during the period. Magnetar Financial LLC raised its position in shares of LivaNova by 8.1% in the 2nd quarter. Magnetar Financial LLC now owns 814,452 shares of the company's stock worth $44,648,000 after acquiring an additional 61,114 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of LivaNova by 3.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after purchasing an additional 25,277 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on LIVN shares. Mizuho lowered their target price on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Needham & Company LLC reiterated a "buy" rating and set a $75.00 target price on shares of LivaNova in a research report on Monday, November 25th. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They set a "buy" rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $69.17.
Read Our Latest Research Report on LivaNova
LivaNova Stock Down 1.6 %
LIVN stock traded down $0.79 during midday trading on Friday, reaching $49.71. 504,805 shares of the company's stock traded hands, compared to its average volume of 417,894. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm's fifty day moving average price is $52.19 and its 200-day moving average price is $51.80. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47. The company has a market cap of $2.70 billion, a price-to-earnings ratio of 118.36 and a beta of 0.98.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
